Tandem Diabetes Care (NASDAQ:TNDM) Raised to “Hold” at Wall Street Zen

Tandem Diabetes Care (NASDAQ:TNDM) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

TNDM has been the subject of a number of other research reports. Citigroup reiterated a “neutral” rating and issued a $15.00 target price (up previously from $11.00) on shares of Tandem Diabetes Care in a research report on Tuesday, October 7th. Truist Financial set a $16.00 price objective on Tandem Diabetes Care and gave the company a “hold” rating in a research report on Wednesday, October 15th. Royal Bank Of Canada lowered their target price on Tandem Diabetes Care from $45.00 to $25.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $24.00 price target on shares of Tandem Diabetes Care in a research note on Monday, September 29th. Four analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $21.25.

Tandem Diabetes Care Stock Up 22.0%

Shares of Tandem Diabetes Care stock opened at $16.26 on Friday. Tandem Diabetes Care has a 1 year low of $9.98 and a 1 year high of $38.28. The company has a market cap of $1.10 billion, a P/E ratio of -5.33 and a beta of 1.51. The company has a current ratio of 2.44, a quick ratio of 1.90 and a debt-to-equity ratio of 2.33. The stock has a 50-day moving average price of $13.68 and a 200 day moving average price of $16.20.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, November 6th. The medical device company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). The company had revenue of $249.25 million for the quarter, compared to analysts’ expectations of $235.80 million. Tandem Diabetes Care had a negative return on equity of 73.97% and a negative net margin of 20.19%.The business’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.35) EPS. Tandem Diabetes Care has set its FY 2025 guidance at EPS. As a group, analysts expect that Tandem Diabetes Care will post -1.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TNDM. Sessa Capital IM L.P. bought a new position in Tandem Diabetes Care in the 1st quarter worth $85,574,000. Ophir Asset Management Pty Ltd bought a new stake in Tandem Diabetes Care during the second quarter valued at about $27,307,000. GW&K Investment Management LLC grew its position in shares of Tandem Diabetes Care by 34.9% in the first quarter. GW&K Investment Management LLC now owns 2,863,987 shares of the medical device company’s stock valued at $54,874,000 after purchasing an additional 740,499 shares during the last quarter. Paradice Investment Management LLC increased its stake in shares of Tandem Diabetes Care by 24.3% in the third quarter. Paradice Investment Management LLC now owns 2,196,468 shares of the medical device company’s stock worth $26,665,000 after purchasing an additional 429,289 shares during the period. Finally, Nuveen LLC bought a new position in shares of Tandem Diabetes Care in the first quarter worth about $5,907,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.